Case of toxic epidermal necrolysis in 75-year-old

0
Allopurinol
Representative image of the effect of toxic epidermal necrolysis on mucosal tissue (eg, lips).

Toxic epidermal necrolysis, adverse reaction caused by allopurinol

A 75-year-old female patient presented with a mildly itching skin rash with associated symptoms of fever, shivering and weakness. According to the patient, the symptoms appeared approximately 3 days after she was prescribed allopurinol. The patient was diagnosed with toxic epidermal necrolysis.

Clinical examination showed a generalised maculopapular exanthema (a widespread rash that occurs on the outside of the body). The rash was recognised to be an adverse drug reaction. Therefore, allopurinol was discontinued. The patient was further put on ambulatory supportive therapy with prednisolone. He was also started on cetirizine. Both the medications did not help with any improvement in symptoms.

Soon after, the patient developed a progressive exanthema

The rash was painful, associated with widespread blistering, skin peeling, mucosal and conjunctival lesions. After presenting to the emergency department recurrently, the patient was referred to the intensive care unit (ICU). The patient’s symptoms were suggestive of toxic epidermal necrolysis. Doctors treated the patient with massive fluid replacement, cyclosporine and prednisolone. Local treatment with polyhexidine and octenidine were also advised. After 7 days of being in the ICU, the patient was referred to the Dermatology Department and was discharged on the 42nd day after admission.

The case study highlights the fact that the prescription of allopurinol is associated with potentially life-threatening complications. For example, Steven Johnson syndrome and toxic epidermal necrolysis. The patients should be immediately referred to dermatology and for multidisciplinary therapy. Toxic epidermal necrolysis is a skin-peeling disease that causes widespread erythema and epidermal blistering that may also be life-threatening.

Allopurinol is the first line of therapy for treatment of gout. Studies have shown that clinical practices tend to overcompensate treatment for asymptomatic patients with elevated serum urate. Consequently, this leads to serious and sometimes even life-threatening reactions.

Source: American Journal of Case Reports

Previous articleFDA Approves Adjuvant Treatment for Melanoma
Next articleAspergillus Mediastinitis: A Rare Postoperative Complication of Cardiac Surgery
Dr. Aiman Shahab is a dentist with a bachelor’s degree from Dow University of Health Sciences. She is an experienced freelance writer with a demonstrated history of working in the health industry. Skilled in general dentistry, she is currently working as an associate dentist at a private dental clinic in Karachi, freelance content writer and as a part time science instructor with Little Medical School. She has also been an ambassador for PDC in the past from the year 2016 – 2018, and her responsibilities included acting as a representative and volunteer for PDC with an intention to make the dental community of Pakistan more connected and to work for benefiting the underprivileged. When she’s not working, you’ll either find her reading or aimlessly walking around for the sake of exploring. Her future plans include getting a master’s degree in maxillofacial and oral surgery, settled in a metropolitan city of North America.

LEAVE A REPLY

Please enter your comment!
Please enter your name here